|
Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Clinical research trials and Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma. Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma clinical trial. Participants frequently get the best healthcare available for their Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma  Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma
Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma
For Condition: Breast Cancer,Colon Cancer,Melanoma
Status: Recruiting
Sponsor(s): Centro Oncologico de Excelencia ,
Synopsis: RATIONALE: Immunotherapy uses different ways to stimulate the immune system and stop cancer cells from growing. Immunotherapy biological extracts may be useful as adjuvant therapy in treating patients who have had surgery for breast cancer, colon cancer, or melanoma. PURPOSE: Phase III trial to study the effectiveness of Corynebacterium granulosum extract as maintenance immunotherapy following surgery in treating patients with breast cancer, colon cancer, or melanoma.
Details: OBJECTIVES: - Determine the survival of patients with colon cancer, breast cancer, or melanoma with minimal residual disease after surgical resection treated with maintenance immunotherapy using Corynebacterium granulosum P40. - Determine leucocyte adherence inhibition, an indication of metastases, over time in patients treated with this regimen. OUTLINE: This is a multicenter study. Patients are stratified by center and are matched with case-controls by disease type and stage. Beginning 2 weeks after surgical resection, patients receive Corynebacterium granulosum P40 subcutaneously weekly for 6 weeks, followed by rest for 3 months. Treatment continues for life. Patients are followed for survival. PROJECTED ACCRUAL: Not specified
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 20 Years/80 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Diagnosis of colon cancer, breast cancer, or melanoma with minimal residual disease (at least 90% of tumor mass resected) after surgical resection - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - 20 to 80 Sex: - Not specified Menopausal status: - Not specified Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Not specified PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
HugoDe Carli, Study Chair, Centro Oncologico de Excelencia
Centro Oncologico de Excelencia *Recruiting*
Gonnet, Buenos Aires, 1987 MB
Argentina
Recruiting Hugo De Carli 021-84-3119
Additional Information:
Study ID Numbers: CDR0000072435; ARG-CO/BR-1
Study Start Date:
Record last reviewed: May 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002455
Other Colon Cancer Studies:
1. A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer
2. Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
3. Phase I Trial in Patients with Metastatic Melanoma of Immunization with a Recombinant Fowlpox Virus Encoding the gp100 Melanoma Antigen
4. A Phase II study of PI-88 in Patients with Advanced Melanoma
5. Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Related Studies:
Other Colon Cancer Clinical Trials
Other Buenos Aires Clinical Trials
Other Gonnet Clinical Trials
Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma
|
|
|
|
|
|
|
|
